Economic Burden of Parkinson’s Disease: A Multinational, Real-World, Cost-of-Illness Study

作者：К. Ray Chaudhuri, Jean‐Philippe Azulay, Per Odin, Susanna Lindvall, Josefa Domingos, Ali Alobaidi, Prasanna L. Kandukuri, Vivek Chaudhari, Juan Carlos Parra, Toru Yamazaki, Julia Oddsdottir, Jack Wright, Pablo Martínez‐Martín · 发表于：Drugs - Real World Outcomes · 年份：2024 · DOI：10.1007/s40801-023-00410-1 · 被引用次数：100 · 研究领域：Parkinson's Disease Mechanisms and Treatments、Voice and Speech Disorders、Parkinson's Disease and Spinal Disorders

BACKGROUND: Parkinson's disease is now one of the fastest-growing neurodegenerative disorders in the developed world, with an increasing prevalence and associated socioeconomic costs. Progression of the disease leads to a gradual deterioration in patients' quality of life, despite optimal treatment, and both medical and societal needs increase, often with the assistance of paid and/or unpaid caregivers. OBJECTIVE: We aimed to quantify the incremental economic burden of Parkinson's disease by disease severity in a real-world setting across differing geographic regions. METHODS: Demographics, clinical characteristics, health status, patient quality of life, caregiver burden, and healthcare resource utilization data were drawn from the Adelphi Parkinson's Disease Specific Program™, conducted in the USA, five European countries, and Japan. RESULTS: A total of 563 neurologists provided data for 5299 individuals with Parkinson's disease; 61% were male, with a mean age of 64 years. Approximately 15% of individuals were deemed to have advanced disease, with significantly more comorbidities, and a poorer quality of life, than those with non-advanced disease. Overall, the mean annual healthcare resource utilization increased significantly with advancing disease, and resulted in a three-fold difference in the USA and Europe. The main drivers behind the high economic burden included hospitalizations, prescription medications, and indirect costs. CONCLUSIONS: People with Parkinson's disea...